

## Efficacy of Varenicline and Nortriptyline in Smoking Cessation: Indirect Comparison of Randomized Controlled Trials

Phiriya Khairod, Saroch Apichartkulchai, Usa Chaikledkaew, Montarat Thavorncharoensap\*  
Department of Pharmacy, Faculty of Pharmacy, Mahidol University, Bangkok 10400  
Thailand

### Abstract

Varenicline is one of the most effective FDA-approved drugs for smoking cessation, but is unavailable or available by prescription only in many countries. On the other hand, nortriptyline, a common antidepressant, can also be used for smoking cessation. To our knowledge, no head-to-head randomised controlled trial comparing the efficacy of varenicline and nortriptyline exists. Thus, the aim of our meta-analysis study is to determine the efficacy of varenicline versus nortriptyline in smoking cessation using indirect comparison method. In our study, randomized controlled trials which compared varenicline or nortriptyline with placebo were included. MEDLINE and the Cochrane Controlled Trials Register were searched from inception to June 2012. Primary outcome was a 7-day-point prevalence of abstinence at week 12, confirmed by end-expiratory carbon monoxide level < 10 ppm and/or urinary cotinine level < 60 ng/ml. Of the 182 articles identified, 13 studies (n = 6,588) were included in the analysis. Results from direct comparison meta-analysis revealed that both varenicline and nortriptyline was significantly more efficacious for smoking cessation than placebo: varenicline (RR = 2.36; 95% CI 1.98 to 2.82), and nortriptyline (RR = 1.86; 95% CI 1.38 to 2.51). On the other hand, result from indirect comparison revealed no statistically significant difference between varenicline and nortriptyline (OR = 1.61; 95% CI 0.82 to 2.91) with regard to a 7-day-point prevalence abstinence at week 12. This study confirmed the benefit and implied the potential use of nortriptyline in smoking cessation. Nevertheless, a head-to-head comparison of nortriptyline and varenicline on long term continuous abstinence rate should be further examined.

**Key word:** indirect comparison, nortriptyline, varenicline, smoking cessation

### INTRODUCTION

Cigarette smoking remains the leading cause of preventable morbidity and premature mortality worldwide.<sup>1</sup> Benefits of quitting on health are significant.<sup>2</sup> At present, nicotine replacement therapy (NRT), sustained-release bupropion, and varenicline are considered first-line pharmacotherapies for smoking cessation<sup>3</sup> while nortriptyline and clonidine are recommended as second line treatment.<sup>4</sup>

Varenicline is a recently developed partial  $\alpha 4\beta 2$  nicotinic acetylcholine agonist.

Recent meta-analyses clearly showed that varenicline was significantly more efficacious for smoking cessation than placebo for continuous abstinence at least 6 weeks (OR 2.88; 95% CI 2.40 to 3.47 and RR 2.27; 95% CI 2.02 to 2.55).<sup>5,6</sup> Moreover, varenicline was also found to be superior to single forms of NRT (OR 1.57; 95% CI 1.29 to 1.91), and to bupropion (OR 1.59; 95% CI 1.29 to 1.96).<sup>6</sup> However, according to post-marketing evidences, varenicline may cause depressed mood, agitation, and suicidal behaviour or ideation.<sup>7</sup> In addition, accessibility of varenicline is limited in many

\*Corresponding author: Department of Pharmacy, Faculty of Pharmacy, Mahidol University, Bangkok 10400, Thailand. Email: montarat.tha@mahidol.ac.th

countries as it has not been approved or it is classified as a prescription drug.

Nortriptyline, a commonly used antidepressant, can also be used for smoking cessation. The advantage of nortriptyline over varenicline is that it is available in most countries worldwide at lower cost. According to a meta-analysis study, nortriptyline was found to be more effective in long term smoking cessation as compared to placebo (OR 2.34; 95% CI 1.61 to 3.41).<sup>8</sup> Its efficacy was also found to be similar to that of nicotine replacement therapy.<sup>8</sup> Furthermore, current evidence clearly indicated that nortriptyline at doses indicated for smoking cessation, is not significantly associated with serious adverse events.<sup>9</sup>

To our knowledge, no direct head-to-head randomised controlled trial comparing the efficacy of varenicline and nortriptyline has been performed. In the absence of direct comparison evidence, indirect comparison is particularly useful.<sup>10-11</sup> The objective of our study is, therefore, to indirectly compare the effects of varenicline versus nortriptyline on smoking cessation, using placebo as a common comparator.

## METHODS

### *Literature search and eligibility criteria*

We searched MEDLINE (1966-July 2012), and Cochrane Controlled Trials Register (1985-July 2012) for all randomized controlled trials comparing varenicline (titrated up to 1 mg, twice daily for 12 weeks) or nortriptyline (titrated up to 75-100 mg per day for 12 weeks) with placebo on the 7-day-point prevalence abstinence rate at week 12 confirmed by end-expiratory carbon monoxide (CO) level  $\leq 10$  ppm and/or urinary cotinine values level  $\leq 60$  ng/ml. The search strategies were performed by combining the Medical Subject Headings (MeSH) of "Smoking Cessation" and relevant keywords of "varenicline" and "nortriptyline". We also manually searched the reference lists of potentially relevant studies and review articles. Only articles published in English that examining the efficacy of varenicline

or nortriptyline among current smokers aged at least 18 years old, who had smoked an average of at least 10 cigarettes per day were included.

### *Assessment of methodological quality and data extraction*

Methodological quality of trails was assessed by two authors (PK and SA) using JADAD score.<sup>12</sup> Only articles with a JADAD score of 3 or higher were included in the meta-analysis. Disagreement was resolved by discussion by MT and UC. Then, PK and SA independently extracted the data using a structured data extraction form. Discrepancies were resolved by discussion with MT. Data was extracted based on intention to treat principle, in which all randomized participants were considered. Authors from some trials were contacted to provide additional data, if necessary.

### *Statistical analysis*


A meta-analysis was conducted using RevMan 5 and WinBUGS 1.4.3 software. Relative Risks (RR) and its associated 95% credible interval (CI) were presented for direct comparison while Odds ratio (OR) and its associated 95% CI was presented for indirect comparison. Random effect model was used whenever there was significant heterogeneity. On the other hand, fixed effect model was used when there was no significant heterogeneity.

## RESULTS

Process of study identification was shown in Figure 1. The search of MEDLINE and the Cochrane Controlled Trials Register provided a total of 182 titles. After reviewing all abstracts, duplicated studies and irrelevant studies were excluded. The remaining 25 studies were included to full text review. Thirteen studies<sup>13-25</sup> met eligibility criteria and were included in the review. After searching bibliographies of included studies, no additional study was further included.

Characteristics of all included 13 studies<sup>13-25</sup> were presented in Table 1. After quality assessment, one study comparing

varenicline to placebo<sup>17</sup> and one study comparing nortriptyline to placebo<sup>24</sup> were excluded from the meta-analysis.



**Figure 1.** Study identification process

### *Direct comparison of varenicline with placebo*

Our estimate was based on nine trials<sup>13-16,18-22</sup> randomizing 5,815 participants. As a result of significant evidence of heterogeneity ( $P < 0.0001$ ,  $I^2 = 80\%$ ), random effect

model was employed to combine the results of included studies. Direct comparison between varenicline and placebo revealed that efficacy of varenicline is significantly higher than that of placebo ( $RR = 2.36$ ; 95% CI 1.98 to 2.82), as shown in Figure 2.

Table 1. characteristics of included studies

Authors/ Years of study	Setting	Participants	Intervention	Outcome measure	JADAD score
Varenicline VS placebo Bolliger CT <i>et al.</i> / 2008-9 <sup>13</sup>	Latin America (Brazil, Colombia, Costa Rica, Mexico, and Venezuela), Africa (Egypt and South Africa), and the Middle East (Jordan, Lebanon, Saudi Arabia, and the United Arab Emirates)	- 588 smokers aged 18-75 years - smoked $\geq 10$ cigarettes/day during the previous 12 months - no cumulative period of abstinence > 3 months in the previous year	varenicline 1 mg bid for 12 weeks	7-day-point prevalence abstinence rate at week 12 and 24 confirmed by expiratory exhaled CO $\leq 10$ ppm	5
Gonzales D <i>et al.</i> / 2003-5 <sup>14</sup>	USA	- 1,025 smokers aged 18-75 years - smoked $\geq 10$ cigarettes per day during the previous 12 months. - fewer than 3 months of smoking abstinence in the past year.	varenicline titrated to 1 mg bid for 12 weeks	7-day-point prevalence abstinence rate at week 12, 24, and 52, confirmed by expiratory exhaled CO $\leq 10$ ppm	5
Jorenby DE <i>et al.</i> / 2003-5 <sup>15</sup>	USA	- 1,027 smokers aged 18-75 years - smoked $\geq 10$ cigarettes per day during the previous 12 months. - fewer than 3 months of smoking abstinence in the past year.	varenicline titrate up to 1 mg bid for 12 weeks	7-day-point prevalence abstinence rate at week 12, 24, and 52, confirmed by expiratory exhaled CO $\leq 10$ ppm - continuous abstinence rate at week 9-12, 9-24, and 0-52.	5
Nides M <i>et al.</i> / 2008 <sup>16</sup>	USA	- 2,052 smokers aged 18-75 years - smoked $\geq 10$ cigarettes/day during the previous 12 months - no period of abstinence > 3 months in the previous year - 647 smokers aged 18 to 65 years - smoked $\geq 10$ cigarettes per day during the previous year	varenicline titrate up to 1 mg bid for 12 weeks	7-day-point prevalence abstinence rate at week 12, 24, and 52, confirmed by expiratory exhaled CO $\leq 10$ ppm	4
Oncken C <i>et al.</i> / 2006 <sup>17</sup>	USA	- 647 smokers aged 18 to 65 years - smoked $\geq 10$ cigarettes per day during the previous year	varenicline titrate up to 1 mg bid for 12 weeks	7-day-point prevalence abstinence rate at week 12, 24, and 52, confirmed by expiratory exhaled CO $\leq 10$ ppm	2


**Table 1.** characteristics of included studies (cont.)

Authors/ Years of study	Setting	Participants	Intervention	Outcome measure	JADAD score
Rennard S <i>et al.</i> / 2008-9 <sup>18</sup>	Argentina, Brazil, Canada, China, Czech Republic, France, Germany, Hungary, Italy, Mexico, Republic of Korea, Taiwan, United Kingdom, and United states	- 659 smokers aged 18 - 75 years - smoked $\geq 10$ cigarettes per day during the previous year - fewer than 3 months abstinence during that time, and were motivated to stop smoking. -714 smokers aged 35-75 years -smoked an average of $\geq 10$ cigarettes daily in the year before enrolment -wanted to stop smoking but had not tried to quit in the past 3 months - had stable, documented CVD (other than hypertension) that had been diagnosed for > 2 months	varenicline titrate up to 1 mg bid for 12 weeks	7-day-point prevalence abstinence rate at week 12 and 24, confirmed by expiratory exhaled CO $\leq 10$ ppm	5
Rigotti NA <i>et al.</i> / 2006 <sup>19</sup>	Argentina, Australia, Brazil, Canada, Czech Republic, Denmark, France, Germany, Greece, Mexico, Netherlands, Republic of Korea, Taiwan, the United Kingdom, and the United States	-504 smokers aged more than 35 years -diagnosis of mild to moderate COPD -motivated to stop smoking. -smoked an average of $\geq 10$ cigarettes/day over the past year with no period of abstinence > 3 months over that time	varenicline titrate up to 1 mg bid for 12 weeks	7-day-point prevalence abstinence rate at week 12, 24, and 52, confirmed by expiratory exhaled CO $\leq 10$ ppm	5
Tashkin DP <i>et al.</i> / 2006-9 <sup>20</sup>	USA, Spain, France, and Italy	-250 smokers aged 18-75 years -smoked $\geq 10$ cigarettes per day during the past year -no period of abstinence > 3 months in the past year	varenicline titrate up to 1 mg bid for 12 weeks	7-day-point prevalence abstinence rate at week 12, 24, and 52, confirmed by expiratory exhaled CO $\leq 10$ ppm	3
Tsai <i>et al.</i> / 2005-6 <sup>21</sup>	Korea, Taiwan		varenicline titrated to 1 mg bid for 12 weeks	7-day-point prevalence abstinence rate at week 12 and 24, confirmed by expiratory exhaled CO $\leq 10$ ppm	5

Table 1. characteristics of included studies (cont.)

Authors/ Years of study	Setting	Participants	Intervention	Outcome measure	JADAD score
Wang C <i>et al.</i> / 2009 <sup>22</sup>	China, Singapore, and Thailand	-333 smokers aged 18-75 years -BMI of 15-38 kg/m <sup>2</sup> and a weight of at least 45.5 kg - smoked on average $\geq 10$ cigarettes per day during the year prior to the screening visit -no period of abstinence $\geq 3$ months -were motivated to stop smoking	varenicline titrated to 1 mg bid for 12 weeks	7-day-point prevalence abstinence rate at week 12 and 24, confirmed by expiratory exhaled CO $\leq 10$ ppm	3
Nortriptyline VS placebo Hall SM <i>et al.</i> / 1998 <sup>23</sup>	USA	- 199 smokers aged 21- 65 years - smoked on average $\geq 10$ cigarettes per day during the previous year. 220 smokers - smoked on average $\geq 10$ abstinence rate at week 12, cigarette per day in the past year	nortriptyline titrate up to 50-100 mg/d for 12 weeks  nortriptyline titrate up to 50 to 100 mg/day for 12 weeks	7-day-point prevalence abstinence rate at week 12, 24, 38, and 64, confirmed by expiratory exhaled CO $\leq 10$ ppm  7-day-point prevalence	4
Hall SM <i>et al.</i> / 2002 <sup>24</sup>				24, 36, and 52, confirmed by expiratory exhaled CO $\leq 10$ ppm and 1 year continuous abstinence rate	2
Wagena <i>et al.</i> / 2002-4 <sup>25</sup>	The Netherlands	-255 smokers at risk for COPD or with COPD, aged 30-70 years -had a smoking history of at least 5 years -smoked on average $\geq 10$ cigarettes per day during the previous year	nortriptyline titrate up to 75 mg/day for 12 weeks	7-day-point prevalence abstinence rate at week 4, 12, and 26, confirmed by urinary cotinine values of 60 ng/mL or less	5






**Figure 2.** Meta-analysis of randomized controlled trials comparing varenicline with placebo on 7-day-point prevalence abstinence rate at week 12

**Direct comparison of nortriptyline with placebo**

This analysis was based on two studies<sup>23,25</sup> randomizing 368 participants. There was no evidence of heterogeneity (P = 0.48, I<sup>2</sup> = 0). For this reason, fixed

effect model was used to pool the results of included studies. Direct comparison between nortriptyline and placebo indicated that nortriptyline is more efficacious than placebo (RR = 1.86; 95% CI 1.38 to 2.51), as found in figure 3.



**Figure 3.** Meta-analysis of randomized controlled trials comparing nortriptyline with placebo on 7-day-point prevalence abstinence rate at week 12

**Indirect comparison of varenicline with nortriptyline**

In an absence of direct evidence comparing efficacy between varenicline and nortriptyline, indirect comparison was conducted using WinBUGs software. This estimation was based on 11 studies<sup>13-16,18-22,23,25</sup> randomizing 6,183 participants. Random effect model was used to account for between-study heterogeneity. Result from indirect treatment comparison revealed no significant difference between varenicline and nortriptyline on the 7-day-point prevalence

abstinence rate at week 12 (OR = 1.61; 95% CI 0.82 to 2.91).

**DISCUSSIONS**

This meta-analysis clearly confirmed that efficacy of both varenicline and nortriptyline on smoking cessation was better than placebo. Notwithstanding the limitations of an indirect comparison study, we found no statistically significant difference between varenicline and nortriptyline on a 7-day-point prevalence abstinence rate at week 12. Consider the cost and the accessibility

issues, this study implied the potential use of nortriptyline in smoking cessation especially in the countries where varenicline has not yet been approved. Nevertheless, there are some limitations worthy of being addressed when interpreting our analysis. Firstly, compared with previous meta-analysis,<sup>5,6,8</sup> the result from this study may over-estimate the efficacy of varenicline and nortriptyline, as only short term outcome (7-day-point prevalence at week 12) was assessed. Secondly, although our review was based on comprehensive literature search and included only studies that had high methodological quality, only articles published in English from MEDLINE and the Cochrane Controlled Trials Register were included. As a result, publication bias and database bias might occur. Lastly, although indirect comparison have been advocated when no direct head-to-head comparison is available,<sup>10-11</sup> there was a concern that indirect comparison may be subjected to greater bias than direct comparison.<sup>26</sup> Therefore, we strongly agreed that interpretation of indirect comparison should be made with caution<sup>27</sup> and recommended that head-to-head comparison of varenicline and nortriptyline on long term smoking cessation outcome deserved further investigation.

#### ACKNOWLEDGEMENTS

We are grateful for the financial support from Faculty of Pharmacy, Mahidol University. We also would like to thank Miss Tikumporn Uavisewong for her help on WinBUGs software.

#### REFERENCES

1. World Health Organization: Tobacco fact sheet No 339. 2013.
2. U.S. Department of Health and Human Services (USDHHS). The Health Benefits of Smoking Cessation. A Report of the Surgeon General. Rockville, MD: U.S. Department of Health and Human Services. Public Health Service, 1990.
3. Fiore MC, Jaén CR, Baker TB, *et al.* Treating Tobacco Use and Dependence: 2008 Update. Quick Reference Guide for Clinicians. Rockville, MD: U.S. Department of Health and Human Services. Public Health Service, 2009.
4. Gratziau C. Review of current smoking cessation guidelines. *European Respiratory society monograph* 2008;42: 35-43.
5. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. *Cochrane Database Syst Rev* 2012;4(CD006103).
6. Cahill K, Stevens S, Perera R, *et al.* Pharmacological interventions for smoking cessation: an overview and network meta-analysis. *Cochrane Database Syst Rev* 2013;5(CD009329).
7. US Food and Drug Administration. Safety alerts for drugs, biologics, medical devices, and dietary supplements. Chantix (varenicline), 2007.
8. Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. *Cochrane Database Syst Rev* 2007;1 (CD000031).
9. Dhippayom T, Chaiyakunapruk N, Jongchansittho T. Safety of nortriptyline at equivalent therapeutic doses for smoking cessation: a systematic review and meta-analysis. *Drug Saf* 2011;34: 199-210.
10. Jansen JP, Fleurence R, Devine B, *et al.* Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 1. *Value Health* 2011;14:417-28.
11. Song F, Altman DG, Glenny AM, *et al.* Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. *BMJ* 2003;326: 472.
12. Jadad AR, Moore RA, Carroll D, *et al.* Assessing the quality of reports of



- randomized clinical trials: is blinding necessary? *Control Clin Trials* 1996; 17:1-12.
13. Bolliger CT, Issa JS, Posadas-Valay R, et al. Effects of varenicline in adult smokers: a multinational, 24-week, randomized, double-blind, placebo-controlled study. *Clin Ther* 2011; 33: 465-77.
  14. Gonzales D, Rennard SI, Nides M, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. *JAMA* 2006;296: 47-55.
  15. Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. *JAMA* 2006; 296:56-63.
  16. Nides M, Glover ED, Reus VI, et al. Varenicline versus bupropion SR or placebo for smoking cessation: a pooled analysis. *Am J Health Behav* 2008;32: 664-75.
  17. Oncken C, Gonzales D, Nides M, et al. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. *Arch Intern Med* 2006;166:1571-7.
  18. Rennard S, Hughes J, Cinciripini PM, et al. A randomized placebo-controlled trial of varenicline for smoking cessation allowing flexible quit dates. *Nicotine Tob Res* 2012;14:343-50.
  19. Rigotti NA, Pipe AL, Benowitz NL, et al. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. *Circulation* 2010;121:221-9.
  20. Tashkin DP, Rennard S, Hays JT, et al. Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trial. *Chest* 2011;139(3):591-9.
  21. Tsai ST, Cho HJ, Cheng HS, et al. A randomized, placebo-controlled trial of varenicline, a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers. *Clin Ther* 2007;29:1027-39.
  22. Wang C, Xiao D, Chan KP, et al. Varenicline for smoking cessation: a placebo-controlled, randomized study. *Respirology* 2009;14:384-392.
  23. Hall SM, Reus VI, Muñoz RF, et al. Nortriptyline and cognitive-behavioral therapy in the treatment of cigarette smoking. *Arch Gen Psychiatry* 1998;55: 683-90.
  24. Hall SM, Humfleet GL, Reus VI, et al. Psychological intervention and antidepressant treatment in smoking cessation. *Arch Gen Psychiatry* 2002;59:930-6.
  25. Wagena EJ, Knipschild PG, Huibers MJ, et al. Efficacy of bupropion and nortriptyline for smoking cessation among people at risk for or with chronic obstructive pulmonary disease. *Arch Intern Med* 2005;165:2286-92.
  26. Bucher HC, Guyatt GH, Griffith LE, et al. The results of direct and indirect treatment comparisons in meta analysis of randomized controlled trial. *J Clin Epidemiol* 1997;50:683-91.
  27. Gartlehner G, Moore CG. Direct versus indirect comparisons: a summary of the evidence. *Int J Technol Assess Health Care* 2008;24:170-7.